'Fertilizing' Bone Marrow Helps Answer Why Some Cancers Spread to Bones 
Science Daily (press release)
The findings provide valuable insight as to why some cancers metastasize to bone, and could eventually result in new metastasis-prevention drugs, said Laurie McCauley, professor in the Department of Periodontics and Oral Medicine at the University of ...
U-M researches say common chemotherapy drug enables tumors in bone marrow AnnArbor.com

all 6 news articles » 

Updated survival results from phase III trial of Alpharadin (radium-223 ... 
Reuters
Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) & ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA) Abstract #4551, ...

and more » 

Denosumab to Delay Bone Mets in Prostate Cancer Stalled 
Medscape
April 27, 2012 ? A new indication for the novel bone drug denosumab (Xgeva, Amgen) ? delaying bone metastases in men with prostate cancer at high risk for this complication ? cannot be approved, according to the US Food and Drug Administration (FDA).
Amgen Receives Complete Response Letter From FDA for XGEVA® sBLA for ... MarketWatch (press release)
FDA Turns Down Expanded Use Of Amgen's Xgeva NASDAQ
Amgen: FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer Capital.gr (press release)

all 37 news articles » 

Algeta to Present at Forthcoming Life Sciences Investor Conferences 
Reuters
Algeta's lead product Alpharadin (radium-223 chloride) is being evaluated as a potential new treatment for cancer patients with bone metastases. Alpharadin is under clinical investigation in castration-resistant prostate cancer (CRPC) patients with ...

and more » 

Celsion Announces Resubmission With Philips Healthcare of Combined IND/IDE ... 
MarketWatch (press release)
ThermoDox(R) combined with MR-HIFU will be investigated for pain palliation in patients with painful bone metastasis. Cancer progresses to the bone in a majority of patients with late-stage breast, prostate or lung cancer, with estimates of between ...

and more » 

FDA Rejects Bone Drug Bid for Metastasis Prevention 
MedPage Today
By Charles Bankhead, Staff Writer, MedPage Today WASHINGTON -- The FDA has turned down an application to expand indications for denosumab (Xgeva) to include prevention of bone metastases in men with castration-resistant prostate cancer.
Denosumab (Xgeva) Not Approved For Metastasis Prevention Medical News Today
FDA turns down new use for Amgen's Xgeva PMLiVE
Amgen's Xgeva suffers US setback; group expands in Ireland Pharma Times
Denver Business Journal 
all 7 news articles » 

New Therapies for Prostate Cancer: The Practicalities 
OncLive
Denosumab is a superior osteoclast inhibitor compared with the current standard for patients with bone metastases, zoledronic acid (Zometa). 7 According to Emmanuel Antonarakis, MBBCh, assistant professor of Oncology, Sidney Kimmel Comprehensive Cancer ...

and more » 

Establishment of a biomarker model for predicting bone metastasis in resected ... 
7thSpace Interactive (press release)
This study was designed to establish a biomarker risk model for predicting bone metastasis instage III non-small cell lung cancer (NSCLC). Methods: The model consists of 105 cases of stage III NSCLC, who were treated and followed up.

 

Algeta reports results for the first quarter 2012 
Reuters
We believe that Alpharadin has the potential to become a major new therapeutic option for cancer patients with bone metastases and we, together with Bayer, are focused on making Alpharadin a success." Highlights of the first quarter 2012: An updated ...

and more » 

Celsion Reports First Quarter 2012 Financial Results 
MarketWatch (press release)
In May, following extensive evaluation of high intensity focused ultrasound (HIFU) in bone cancer patients, Celsion announced the joint resubmission with Philips Healthcare of a combined IND/IDE proposal for a Phase II Study in prostate metastases to ...
Celsion Announces Resubmission With Philips Healthcare of Combined IND/IDE ... Benzinga

all 4 news articles »